The study was done to examine the efficacy and safety of combination therapy with the GLP-1 receptor agonist exenatide plus the TZD pioglitazone versus basal-bolus insulin in poorly controlled type 2 diabetic patients with very high HbA1c (HbA1c>10%) on metformin plus sulfonylurea and long duration of disease.
